Quinidine Gluconate

Inquiry

Cat Number

API7054253

CAS Number

7054-25-3

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

7054-25-3

EINECS

230-333-9

Molecular Formula

C26H36N2O9

Molecular Weight

520.6

Smiles

COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O

Melting Point

175-176℃

General Description

Quinidine Gluconate is the gluconate salt of quinidine, a Class Ia antiarrhythmic agent derived from the bark of the cinchona tree. As a gluconate salt, it has greater solubility and is used in controlled-release oral formulations and intravenous infusions for the management of cardiac arrhythmias. It exerts multiple electrophysiological effects including sodium channel blockade and potassium channel modulation.

Mechanism of Action

Quinidine Gluconate exerts Class Ia antiarrhythmic effects by blocking cardiac sodium (Nav1.5) channels, slowing the rate of phase 0 depolarization (reduced Vmax) in Purkinje fibers and working myocardium. It also blocks potassium channels (IKr, IKs), prolonging the action potential duration and effective refractory period. Additionally, it exerts vagolytic and mild alpha-adrenergic blocking effects, which contribute to its cardiovascular profile.

Application

Quinidine Gluconate is indicated for the treatment and prevention of supraventricular arrhythmias (including atrial fibrillation and AV nodal reentrant tachycardia) and ventricular arrhythmias (ventricular tachycardia, premature ventricular contractions).

Atopegant, an oral CGRP receptor antagonist for migraine prevention, is a substrate of P-gp and CYP2D6. This Phase 1 open-label study in 33 healthy adults evaluated the effect of quinidine (a strong P-gp and CYP2D6 inhibitor) on atopegant pharmacokinetics. Co-administration of quinidine gluconate did not significantly change atopegant maximum plasma concentration. Overall systemic exposure (AUC) of atopegant increased by 25%, which was not clinically relevant. Atopegant did not alter steady-state plasma concentrations of quinidine. The increase in atopegant exposure during co-administration is attributed to inhibition of CYP2D6 (a minor contributor to atopegant clearance) and P-gp. Co-administration showed no unexpected tolerability findings. These findings indicate that no dose adjustment is needed when atopegant is co-administered with P-gp/CYP2D6 inhibitors.

Fig. 1 Mean (SD) plasma atogepant concentrations when administered alone or co-administered with Quinidine Gluconate inhealthy participants. (Boinpally R.; et al. 2024)

References

Boinpally R, et al. Pharmacokinetics and safety of atogepant co‐administered with quinidine gluconate in healthy participants: a phase 1, open‐label, drug‐drug interaction study. Clinical Pharmacology in Drug Development, 2024, 13(8): 930-937.

What is the recommended storage condition for Quinidine Gluconate?

It should be stored at controlled room temperature in a well-sealed container, protected from moisture and direct light, to maintain its chemical integrity throughout the shelf life.

Can we obtain batch-specific analytical data for Quinidine Gluconate?

Batch-specific COA documents are standard with every shipment. Additional analytical reports, including HPLC chromatograms or spectral data, may be provided upon request.

What is the minimum order quantity (MOQ) for Quinidine Gluconate?

Flexible MOQ options are available to support both early-stage research and large-scale manufacturing needs. Our team can tailor order quantities to match your specific requirements.

Does Quinidine Gluconate have pharmacopoeial monograph compliance?

Material meeting applicable pharmacopoeial specifications or equivalent internal quality standards can be supplied; please contact us with your specific compendial requirements.